Creatine might help fight depression, but let's stay cautious

Introduction: a gym supplement now intriguing psychiatry

A scientific review that revives an unexpected debate

Creatine, known for decades mainly as a supplement for bodybuilders, is now the subject of fresh scientific attention: could it help treat depression? A systematic review published in the journal Brain Medicine, led by researcher Bassam Jeryous Fares of the University of Ottawa and reported by ScienceDaily on June 30, 2026, examined this exact question.

This review did not conduct any new clinical experiment: it analyzed six published reports, corresponding to five randomized clinical trials, in an attempt to draw a clear trend from data already available on the subject.

Why this topic deserves careful popularization

Faced with a headline as catchy as "creatine could fight depression," the temptation to oversimplify is strong. This commentary aims precisely to avoid that trap: to explain what this data actually shows, without giving in to either sensationalism or excessive skepticism.

The hope raised by this research is real, but it must be measured against the still-modest size of the available studies and the methodological caution displayed by the researchers themselves.

What the review actually examined

Five trials, two hundred thirty-eight participants, five countries

The review analyzed five randomized clinical trials conducted in South Korea, the United States, Brazil, Israel, and India, totaling 238 participants, of whom 126 received creatine and 112 received a placebo, according to data detailed by ScienceDaily. The average age of participants was 36, and most were women.

Four of these trials focused on major depressive disorder, while a fifth concerned a depressive episode within bipolar disorder, an important clinical distinction for understanding the true scope of the results obtained.

Why the researchers did not statistically pool the data

An important methodological fact: the researchers did not pool all the data into a single overall statistical analysis, due to substantial differences in design and method between the studies, a choice that reflects commendable scientific rigor rather than an awkward limitation to hide.

This methodological decision means, in practice, that each trial must be examined individually rather than seeking a single simplified conclusion, an essential nuance for understanding why the overall results are described as "mixed" by the authors themselves.

The two trials that show a real benefit

A marked improvement among women on antidepressants

The first positive trial found that women with major depressive disorder taking 5 grams of creatine per day alongside escitalopram, a common antidepressant, showed a more pronounced reduction in their symptoms after eight weeks, compared to those receiving the antidepressant alone with a placebo.

This improvement corresponded to a notable effect size, measured by a Cohen's d of 1.13 on the Hamilton depression scale, a statistically solid result that also coincided with a higher number of participants achieving full remission of their symptoms.

A second trial combining creatine and cognitive behavioral therapy

The second positive trial tested combining creatine with cognitive behavioral therapy, a recognized mental health treatment approach, and likewise showed a greater reduction in depressive symptoms on a standard rating scale, compared to therapy alone plus a placebo.

These two positive results, though limited in number, suggest a potentially real mechanism of action rather than a simple statistical fluke, which justifies the growing scientific interest in this line of research.

The three trials that showed no benefit

No improvement among treatment-resistant patients

One trial tested doses of 5 and 10 grams of creatine per day in patients whose depression had not responded to standard antidepressant medications, finding no significant improvement in symptoms at either dose.

This negative result is a reminder of an important reality in psychiatry: a complementary treatment that shows promise in some clinical contexts does not necessarily work in the most treatment-resistant patients, a population that remains one of the field's greatest clinical challenges.

No benefit in adolescent girls or in bipolar patients

Another trial conducted among adolescent girls showed no benefit of creatine over placebo, even when testing different doses, while a trial involving patients with bipolar disorder likewise revealed no measurable improvement in depressive symptoms.

More concerning still, two participants with bipolar disorder who received creatine developed episodes of hypomania or mania, a safety signal that calls for particular caution with this specific population of patients.

What the review's lead researcher says, precisely

An interesting signal, not a clinical verdict

Researcher Bassam Jeryous Fares, quoted by ScienceDaily, sums up the current state of knowledge with commendable clarity: "The signal is interesting, but it's not a verdict. Two trials pointed one way and three pointed another. This isn't the kind of evidence you change clinical practice on. It's the kind that says the question deserves more exploration."

This cautious phrasing, typical of responsible scientific communication, contrasts with the sometimes more assertive headlines carried by certain media outlets, a gap that illustrates the importance of always tracing back to the primary source of a study before drawing hasty conclusions.

A generally reassuring safety profile, with nuances

Co-author Nicholas Fabiano specifies that "creatine appears to be a safe intervention. The adverse effects we observed were limited to mild gastrointestinal discomfort. We cannot yet reliably say that creatine helps with depressive symptoms, nor whether the results are generalizable to everyone."

This dual nuance, reassuring safety on one hand and persistent uncertainty about effectiveness on the other, perfectly sums up the current, still provisional, state of scientific knowledge on this precise topic.

The theoretical biological mechanism behind this lead

Brain energy, a stimulating field of hypotheses

On the biological front, researchers point to several theoretical mechanisms that could explain a potential effect of creatine on mood: its role in regenerating adenosine triphosphate, the brain's main cellular energy source, as well as possible interactions with the dopamine and serotonin systems, two neurotransmitters directly involved in mood regulation.

These biological hypotheses remain, in the researchers' own words, purely theoretical at this stage, meaning they offer a plausible line of explanation without constituting proof of creatine's actual mechanism of action on the human brain.

Why scientific caution is essential here

Research into the brain metabolism of creatine remains a relatively young scientific field, and the changes observed in some studies do not yet allow for a clear, definitive causal link to be established between supplementation and an actual improvement in depressive symptoms among affected patients.

This methodological caution, far from being a discouraging obstacle, is precisely the driving force that justifies pursuing deeper research into this still largely misunderstood biological mechanism.

The methodological limits holding back hasty conclusions

Trials too small to reach a definitive verdict

One of the main limitations highlighted by the review's authors concerns the relatively modest size of the clinical trials analyzed, a factor that increases the risk that certain positive or negative results reflect random statistical fluctuations rather than a real, reproducible biological effect of creatine.

This limitation, common in psychiatric research on new interventions, does not invalidate the results obtained, but calls for a cautious reading that avoids generalizing too quickly from still-limited samples.

A gender-imbalanced population and a limited duration

The studies analyzed included a disproportionate share of women compared to men, which limits the ability to generalize the results to the broader population, while the trial duration, generally limited to eight weeks, does not allow for evaluating the potential effects of prolonged treatment over several months or years.

These methodological limitations, clearly identified by the researchers themselves, explain why the review explicitly calls for larger, longer-duration clinical trials before more definitive clinical conclusions can be drawn.

What this concretely means for patients today

Not yet a broad clinical recommendation

Despite the interest sparked by these preliminary results, the review's authors are clear: current evidence remains too limited to justify widespread use of creatine as a treatment for depression in routine clinical practice, an essential nuance that any patient interested in this option should keep in mind.

This caution does not mean the lead should be abandoned — quite the opposite — but it is a reminder that no supplement, however promising on paper, should replace rigorous, personalized medical follow-up for a condition as serious as depression.

The importance of consulting before any self-medication

Anyone considering adding creatine to their treatment for depression should absolutely discuss it beforehand with a healthcare professional, particularly given the safety signal observed in patients with bipolar disorder who developed hypomanic symptoms.

This recommendation for caution is not a mere defensive reflex: it directly reflects the limitations and nuances identified by the researchers themselves in their own review of the available scientific literature.

The broader context of research on supplements and mental health

A growing trend toward exploring non-standard pharmaceutical options

This review on creatine fits into a broader scientific trend that has, for several years, explored the potential of various dietary supplements and non-standard pharmaceutical interventions, such as certain omega-3s or vitamin D, to complement existing treatments for depression, generally with similarly mixed results requiring further research.

This broader research momentum reflects a legitimate desire to diversify the therapeutic options available to patients, particularly those whose response to standard pharmaceutical treatments remains insufficient or comes with side effects that are difficult to tolerate.

Why science popularization must resist media hype

Every new promising lead in this field risks being quickly seized upon by enthusiastic commercial messaging, whether from dietary supplement manufacturers or wellness content platforms, which calls for particular vigilance from journalists and science communicators tasked with relaying this information to the general public.

This editorial vigilance, deliberately applied here, aims to convey the measured hope that these results deserve, without ever turning an uncertain preliminary signal into a definitive, premature therapeutic promise.

What future research will need to clarify

Larger, longer-duration trials are needed

The review's authors explicitly call for larger-scale randomized clinical trials, including more participants and extending beyond the usual eight weeks, to determine whether the benefits observed in some trials persist, or even grow, over a longer treatment period.

This clear methodological recommendation lays out a precise roadmap for researchers wishing to explore this lead further, rather than settling for the currently available data, which remains too fragmented to definitively settle the question.

Exploring the combination with physical exercise

Researchers also suggest studying creatine in combination with physical exercise, a particularly interesting avenue given the already well-established benefits of regular physical activity on mental health, and one that could potentially reveal synergistic effects not yet explored to date.

This future research direction, if it materializes, could offer particularly accessible and inexpensive combined therapeutic options for patients, a significant public health issue in a context where access to mental health care often remains limited.

A dose that doesn't necessarily guarantee a better result

The myth that a higher dose is automatically more effective

Current data suggests that a higher dose of creatine does not necessarily lead to a better clinical outcome, as illustrated by the trial that unsuccessfully tested doses of 5 and 10 grams per day in patients resistant to standard antidepressant treatments.

This observation contradicts the widespread intuition that "more is better" when it comes to supplements, a useful reminder that human biology rarely follows a simple linear, proportional dosing logic.

The importance of standardizing future dosing protocols

Given this uncertainty about the optimal dose, researchers are calling for more rigorous standardization of the protocols used in future clinical trials, to allow for more reliable comparisons between studies and to identify, if applicable, the dose most likely to produce a real, reproducible clinical benefit.

This methodological requirement, though technical, directly determines the quality and reliability of the scientific knowledge that will emerge from future research on this precise topic.

What this research teaches us about modern psychiatry

A discipline increasingly open to complementary approaches

This review on creatine illustrates a broader evolution in modern psychiatry, increasingly willing to seriously explore approaches that complement standard pharmaceutical treatments, without abandoning the methodological rigor that must frame any serious clinical evaluation.

This disciplinary openness, far from being a concession to skepticism toward conventional medicine, instead reflects growing scientific maturity, capable of objectively evaluating unconventional leads with the same standards of evidence as any standard medication.

Why this rigor ultimately benefits patients

This methodological rigor, while it may seem frustrating for patients seeking quick solutions to a condition as grueling as depression, is in reality the best protection against false promises and unproven treatments that could, in the worst case, delay access to genuinely effective care.

It is precisely this rigorous scientific discipline that will, in time, allow us to determine with greater certainty whether creatine deserves a legitimate place in the therapeutic arsenal against depression.

The economic and practical stakes of an already widely available supplement

An inexpensive product already accessible over the counter

Unlike many experimental psychiatric treatments, creatine has the practical advantage of already being widely available over the counter at a relatively modest cost, which, if its effectiveness were to be confirmed by larger trials, could make it a particularly accessible complementary therapeutic option for many patients around the world.

This economic accessibility is a significant argument in favor of continuing research on this topic, in a context where the cost of some newer psychiatric treatments often remains prohibitive for a large part of the world's population.

A risk of premature marketing to watch closely

This accessibility and low cost also create a real risk of premature commercial exploitation by certain dietary supplement manufacturers, who might be tempted to promote creatine as an established treatment for depression before science has definitively settled the question.

This commercial vigilance is a necessary complement to the scientific vigilance already exercised by the researchers themselves, in order to protect patients from marketing claims that would go well beyond what current data can actually support.

What patient associations recommend in the meantime

Never stop an ongoing treatment without medical advice

Mental health associations consistently remind patients that no one should stop or change their regular antidepressant treatment based solely on preliminary results like those presented in this review, an essential precaution to avoid any avoidable relapse linked to prematurely stopping an effective treatment.

This recommendation for caution, valid for any new emerging therapeutic lead in mental health, applies with particular relevance to creatine, whose real effectiveness has yet to be confirmed by more extensive, larger-scale research.

The importance of dialogue with one's treating physician

For patients interested in this option, the most responsible approach is to discuss it openly with their doctor or treating psychiatrist, who can assess, on a case-by-case basis, the relevance of a supervised trial of creatine alongside existing treatment, taking into account each patient's specific medical profile.

This individualized approach, rather than a hasty generalization from still-preliminary results, remains the safest and most responsible way to explore this promising but still uncertain therapeutic lead.

Conclusion: measured hope, not a miracle cure

A real lead worth following closely

This review on creatine and depression perfectly illustrates what responsible scientific communication should look like: neither blind enthusiasm for a miracle cure, nor categorical rejection of a promising research lead, but an honest acknowledgment of mixed results, methodological limitations, and the work that remains before definitive clinical conclusions can be drawn.

The two positive trials, encouraging as they are, are not yet enough on their own to transform current clinical practice, but they amply justify pursuing larger, more rigorous research into this still-emerging therapeutic lead.

What to watch in the coming years

The larger-scale clinical trials called for by researchers will be the most reliable indicator of whether creatine truly deserves a place in the therapeutic arsenal against depression, or whether the positive results seen so far ultimately amount to statistical coincidence rather than a real, reproducible biological effect.

Until then, measured hope remains the only scientifically honest stance in the face of this still-young research, promising but decidedly incomplete.

By Maxime Marquette, columnist

Columnist's transparency note

On the limits of this commentary

This text relies exclusively on the systematic review published in Brain Medicine and reported by ScienceDaily, as well as verifiable supplementary medical sources. I do not have access to the complete raw data of the clinical trials analyzed, and I stick strictly to the conclusions reported by the researchers themselves, without extrapolating beyond what these sources allow me to state.

On my stance on this medical topic

I am neither a physician nor a neuroscience researcher, and I make no claim to clinical expertise to personally assess the relevance of a creatine-based treatment for depression. My role, as a columnist, is to popularize this research for a general audience, with the measured hope and caution this topic absolutely requires.

Sources

Primary sources

ScienceDaily, scientists say creatine may help fight depression — June 30, 2026

PubMed Central, systematic review on creatine and depression

PubMed, scientific publication on creatine supplementation and depressive symptoms

Secondary sources

Healthline, creatine shows promise treating depression symptoms

News-Medical, can creatine help with depression, new review says results are inconclusive

ScienceDaily, health and medicine section